Business Context and Reporting Period
This Form 8-K Current Report, dated February 2, 2012, is filed by Neuralstem, Inc. (Note: The request metadata lists "Palisade Bio, Inc.", but the filing text explicitly identifies the registrant as Neuralstem, Inc.). The report details the entry into a material definitive agreement regarding a registered public offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $5,200,000 from the sale of 5,200,000 units.
- Net Proceeds: Estimated at $4,910,000 after deducting fees and expenses.
- Unit Price: $1.00 per unit.
- Unit Composition: One share of common stock and one warrant to purchase one share at an exercise price of $1.02.
- Placement Agent Fees: $260,000 cash fee (5% of gross proceeds) plus a warrant to purchase 312,000 shares (6% of shares issued).
- Expense Reimbursement: $15,000 payable to the Placement Agent.
- Warrant Terms: Investor warrants are exercisable after six months with a 5-year term. The Placement Agent warrant is exercisable after six months until October 14, 2015, at an exercise price of $1.25.
Material Changes
The filing reports a significant capital raise event. The company entered into securities purchase agreements with institutional and accredited investors on February 3, 2012, for the sale of 5,200,000 units. This transaction represents a new source of liquidity for the company, with the offering expected to close on or about February 10, 2012.
Outlook, Risks, and Management Commentary
The offering is registered under a Form S-3 Registration Statement declared effective on October 14, 2010. The closing of the transaction is subject to customary closing conditions. The filing notes that the warrants do not contain "price protection provisions" regarding subsequent securities issuances. A press release regarding the offering was issued on February 6, 2012.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected February 10, 2012) and confirm receipt of net proceeds.
- Review the Prospectus Supplement filed on February 6, 2012, for full terms of the offering.
- Confirm the dilution impact of the 5,200,000 new shares and the 5,512,000 total warrants issued (including the Placement Agent warrant).
- Check subsequent filings for any changes to the closing conditions or the use of proceeds.